A Phase 4 interventional study of Intravenous ketamine and Cognitive training in Suicide, Attempted, sponsored by Rebecca Price. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-03-24.
Sponsored by Rebecca Price · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 149 studies in Suicide, Attempted with a site in United States — 53 open to participants now, 58 under way, 1 of them phase 3. Suicide, Attempted · United States.
Among the 149 studies in Suicide, Attempted with a site in United States, this one is the 46th largest by enrollment of the 140 interventional ones that give a count, is one of 12 that started in 2021, is one of 3 in phase 4, reaches primary completion later than 12 of the 57 other live ones, and was the 67th registered.
281 studies on the registry are indexed under Suicide, Attempted; 90 are open to participants now.
Browse Suicide, Attempted studies →53 of the 149 studies in Suicide, Attempted with a site in United States are open now. Recruiting first, the newest first:
Dartmouth-Hitchcock Medical Center · Sites in United States
Ages 12+
Massachusetts General Hospital · Sites in United States
Ages 18+
University of Texas Southwestern Medical Center · Sites in United States
Ages 13–17
University of Michigan · Sites in United States
Ages 18–65
Ohio State University · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 67 Suicide, Attempted studies recruiting now, 34 (51%) set no upper age limit and 32 (48%) stop at 75 or younger; 28 take children under 18; 11 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
149 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 8 · Phase 3 6 · Phase 4 3
First in 1999; this study’s year is marked. 12 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 200 is above the median of 129 across 224 interventional studies indexed under Suicide, Attempted.
Median enrollment 117 across the 140 interventional studies, 225 across the 7 observational. Of the 87 that completed or were terminated, 30 (34%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 149 have an industry lead sponsor. The 10 most frequent:
Rebecca Price is the lead sponsor of 7 studies on the registry; 1 is open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 4 (80%) have results posted.
Rebecca Price has 2 studies filed under Suicide, Attempted — fewer than ten, so there is no comparison to draw.
30 of the studies in Suicide, Attempted with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04763343Phase 3Tatiana Falcone, MDKetamine Treatment of Youth Suicide Attempters | 2027-02-28 |
| NCT07170657University of Texas Southwestern Medical CenterTeen Recovery Through Inspiration, Support, and Empowerment | 2026-11 |
| NCT06460220Jennifer HughesSAFETY-Parent: Online Learning Module to Support Parents of Suicidal Youth | 2026-12 |
| NCT06285708Ohio State UniversityEnhancing the Effectiveness of Prolonged Exposure Among Suicidal Individuals With PTSD | 2026-12 |
| NCT04578938Rebecca PriceKetamine + Cognitive Training for Suicidality in the Medical Setting | 2026-12-02 |
Add all 30 to your calendar (.ics) → With an account.
Among the 149 studies in Suicide, Attempted with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This project seeks to identify the acute and longer-term impact of a single dose of intravenous ketamine among suicidal patients referred for psychiatric consultation/liaison in the medical inpatient setting. The investigators will then test whether ketamine's rapid effects can be extended by introducing helpful information delivered by a computer-based training protocol. This work could ultimately lead to the ability to treat suicidality more efficiently and with broader dissemination by rapidly priming the brain for helpful forms of learning.
NOTE: Edits were made to the outcome measures sections to improve clarity regarding the a priori analytic plan with respect to the "Time Frame" of measurements and to reduce redundancies. Timepoints that will be analyzed as trajectories over windows of time and measurements that will be analyzed as composites are now more clearly specified. The previous entries correctly identified all relevant measures and timepoints, but implied incorrectly that each timepoint/measure would be analyzed in isolation.
03/19/26: Edit to upper age limit made to correct a previous data entry error and align with IRB-approved protocol.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Participants who receive ketamine will:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
MMSE and MoCA
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Intravenous ketamine · Behavioral: Cognitive training
Drug: Intravenous ketamine · Behavioral: Sham Training
Behavioral: Cognitive training
Behavioral: Sham Training
Single subanesthetic infusion of ketamine (0.5mg/kg)
8 sessions of computer-based cognitive training
8 sessions of computer-based sham training
Scale for Suicide Ideation
suicidal ideation/thoughts; range 0-38; high score=worse outcome
Time frame: Trajectories from 24hrs through 1 month
Montgomery Asberg Depression Rating Scale
depression severity; range 0-60; high score=worse outcome
Time frame: Trajectories from 24hrs through 1 month
Suicidal behaviors: medical chart review and Columbia Suicide Severity Rating Scale (CSSRS)
composite measure of # unique occurrences of any suicidal outcome (recorded via either measure) including: re-attempt, re-hospitalization for suicidality, suicide behaviors, or completed suicide
Time frame: Trajectories from 24hrs through 12 months
Adult Suicide Ideation Questionnaire
suicidal ideation/thoughts; range 0-150; high score=worse outcome
Time frame: Trajectories from 24hrs through 12 months
Quick Inventory of Depressive Symptoms
Self-reported depression (range: 0-27; higher scores = worse outcome)
Time frame: Trajectories from 24hrs through 12 months
Scale for Suicide Ideation
suicidal ideation/thoughts; range 0-38; high score=worse outcome
Time frame: Trajectories from 1 month through 12 months
Montgomery Asberg Depression Rating Scale
depression severity; range 0-60; high score=worse outcome
Time frame: Trajectories from 1 month through 12 months
Implicit Association Test
performance-based "target engagement" measure of suicidal cognition; range = -inf-inf; high score=worse outcome
Time frame: Trajectories from 24hrs through 1 week
Implicit Association Test
performance-based "target engagement" measure of suicidal cognition; range = -inf-inf; high score=worse outcome
Time frame: Trajectories from 1 week through 12 months
Acceptability: infusion
self-report slider scale rating; range = 0-100; high score=better rating
Time frame: Post-CT assessment (approximately +5 days post-randomization)
Satisfaction: infusion
self-report slider scale rating; range = 0-100; high score=better rating
Time frame: Post-CT assessment (approximately +5 days post-randomization)
Future likelihood of use: infusion
self-report slider scale rating; range = 0-100; high score=better rating
Time frame: Post-CT assessment (approximately +5 days post-randomization)
Ease of use: Cognitive Training
self-report slider scale rating; range = 0-100; high score=better rating
Time frame: Post-CT assessment (approximately +5 days post-randomization)
Helpfulness: Cognitive Training
self-report slider scale rating; range = 0-100; high score=better rating
Time frame: Post-CT assessment (approximately +5 days post-randomization)
Satisfaction: Cognitive Training
self-report slider scale rating; range = 0-100; high score=better rating
Time frame: Post-CT assessment (approximately +5 days post-randomization)
Future likelihood of use: Cognitive Training
self-report slider scale rating; range = 0-100; high score=better rating
Time frame: Post-CT assessment (approximately +5 days post-randomization)
PROMIS Pain Intensity score
PROMIS Pain Intensity Short Form scale T-score (range=0-100; higher score=worse pain)
Time frame: 24 hrs post-randomization
PROMIS Pain Intensity score
PROMIS Pain Intensity Short Form scale T-score (range=0-100; higher score=worse pain)
Time frame: Post-CT assessment (approximately +5 days post-randomization)
PROMIS Neuropathic Pain Quality
PROMIS Neuropathic Pain Quality scale T-score (range=0-100; higher score=worse pain)
Time frame: 24 hrs post-randomization
PROMIS Neuropathic Pain Quality
PROMIS Neuropathic Pain Quality scale T-score (range=0-100; higher score=worse pain)
Time frame: Post-CT assessment (approximately +5 days post-randomization)
PROMIS Nociceptive Pain Quality
PROMIS Nociceptive Pain Quality scale T-score (range=0-100; higher score=worse pain)
Time frame: 24 hrs post-randomization
PROMIS Nociceptive Pain Quality
PROMIS Nociceptive Pain Quality scale T-score (range=0-100; higher score=worse pain)
Time frame: Post-CT assessment (approximately +5 days post-randomization)
Plan to share: No
No publications or documents are linked to this record.
Started Mar 2021 (actual). Primary completion is estimated for Dec 2026, 68 months after the start.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ketamine
Rebecca Price